Levodropropizine – does the composition of the drug matter? Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Jun 30, 2024
DOI: https://doi.org/10.24292/01.MF.0224.07
Keywords:
levodropropizine, cough, syrup, children, compliance

Main Article Content

Adam J. Sybilski
1. Klinika Pediatrii i Alergologii, Państwowy Instytut Medyczny MSWiA w Warszawie. 2. II Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie

Abstract

Cough is the most common symptom of respiratory diseases, and the cough reflex is one of the basic physiological mechanisms facilitating the clearance of the respiratory tract. Indications for the use of antitussive drugs are limited and apply only to dry, persistent cough. However, studies show that the use of antitussive drugs is effective. Among antitussive drugs, levodropropizine holds a special place. It is a non-opioid antitussive agent that acts peripherally. Meta-analyses have proven its effectiveness in both children and adults, showing statistically significantly better results compared to centrally acting antitussive drugs in terms of effectiveness in reducing cough intensity, its frequency and nocturnal awakenings. The features that an ideal drug that is effective in children should have are: effectiveness, safety, experience with the use of the preparation, a form appropriate to the patient’s age and abilities, precisely defined dosage, no sugar in the syrup, alcohol and dyes, good taste and simple dosing. There is such a preparation.

Article Details

How to Cite
Sybilski, A. J. (2024). Levodropropizine – does the composition of the drug matter?. Medycyna Faktow (J EBM), 17(2(63), 211-213. https://doi.org/10.24292/01.MF.0224.07
Issue
Vol 17 No 2(63) (2024)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Marseglia GL, Manti S, Chiappini E et al. Acute cough in children and adolescents: A systematic review and a practical algorithm by the Italian Society of Pediatric Allergy and Immunology. Allergol Immunopathol (Madr). 2021; 49(2): 155-69.
2. Doniec Z, Mastalerz-Migas A, Krenke K et al. Rekomendacje postępowania diagnostyczno-terapeutycznego w kaszlu u dzieci dla lekarzy POZ. Lekarz POZ. 2016; 2(4): 305-21.
3. Malesker MA, Callahan-Lyon P, Ireland B, Irwin RS. Pharmacologic and Nonpharmacologic Treatment for Acute Cough Associated With the Common Cold: CHEST Expert Panel Report. Chest. 2017; 152(5): 1021-37.
4. Birring S, de Blasio F, Dicpinigaitis PV et al. Antitussive therapy: A role for levodropropizine. Pulm Pharmacol Ther. 2019 Jun; 56: 79-85.
5. Mannini C, Lavorini F, Zanasi A et al. A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough. CHEST 2017; 151(6): 1288-94.
6. Zanasi A, Lanata L, Fontana G et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015; 10(1): 19.
7. Muśko M, Sznitowska M. Postacie leków pediatrycznych. Część I. Wymagania i podstawowe problemy – dawkowanie, połykanie, smak. Farm Pol. 2010; 66(3): 215-20.